导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.30% | 2541/4775 |
| 近一周 | 0.48% | 2558/5443 |
| 近一月 | -2.03% | 2403/5404 |
| 近一季 | -2.85% | 2379/5200 |
| 近半年 | 1.55% | 1686/4909 |
| 近一年 | 6.30% | 2248/4351 |
| 近两年 | 48.63% | 1619/2950 |
| 近三年 | 30.66% | 1130/2240 |
| 成立以来 | 52.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.60% 3304/4961 |
12.34% 2191/5312 |
- - |
- - |
| 2025 | 19.92% 2167/4813 |
-0.96% 2492/3635 |
2.15% 1813/4076 |
17.98% 2380/4524 |
0.46% 1984/4813 |
| 2024 | 16.48% 805/3463 |
2.71% 724/2808 |
-1.23% 995/3014 |
16.60% 1404/3129 |
-1.53% 1740/3463 |
| 2023 | -8.90% 1071/2656 |
4.21% 1021/2280 |
-3.77% 892/2385 |
-2.84% 766/2515 |
-6.49% 1799/2655 |
| 2022 | -18.16% 669/2207 |
-13.80% 843/1919 |
6.75% 614/2016 |
-13.23% 860/2113 |
2.51% 913/2208 |
| 2021 | -1.67% 814/1822 |
-2.71% 693/1255 |
4.13% 919/1330 |
-5.11% 779/1466 |
2.29% 630/1822 |
| 2020 | 32.74% 477/1250 |
-9.60% 694/1028 |
13.37% 624/1067 |
14.10% 299/1164 |
13.52% 353/1184 |
| 2019 | 36.56% 355/1092 |
26.20% 424/739 |
0.23% 179/788 |
0.87% 450/850 |
7.04% 496/918 |
| 2018 | - - |
- - |
- - |
-1.02% 224/660 |
-11.86% 372/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰沪深300指数C VS. 长安沪深300非周期A(740101) |